|
Actelion was founded in December 1997 and has its headquarters in Allschwil near Basel (Switzerland). Its CEO and co-founder is cardiologist Jean-Paul Clozel. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. The company name might be a reminder for its first product, an endothelian receptor antagonist and the verb "action", "act upon". Actelion was initially financed with venture capital provided through a syndicate including Sofinnova and HealthCap. Actelion specializes in orphan diseases. Often R&D investments in such diseases are low because companies see no ROI. Obviously, this is a serious problem for patients affected by a rare disease. Orphan diseases often affect very vulnerable patient groups such as children; Actelion keeps investing in such areas: Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. The Swiss affiliate is located in Baden, the German affiliate in Freiburg, the Austrian one in Vienna, the French one in Paris and the UK affiliate is located in London In 2006, the company established the Actelion Endothelin Research Award programme which supports selected clinical research projects. ==Medicines== Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases: * ''Tracleer'' (bosentan): Tracleer was the first oral treatment approved for pulmonary arterial hypertension, a rare, chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. It is a dual endothelin receptor antagonist, see also: Endothelin receptor antagonist. * ''Zavesca'' (miglustat): is currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Type 1 Gaucher disease is a rare and debilitating metabolic disorder. * ''Ventavis'' (iloprost): Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms. * ''Veletri'' (epoprostenol for injection): is approved by the U.S. Food and Drug Administration (FDA) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Actelion」の詳細全文を読む スポンサード リンク
|